echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts the transition from MCI to dementia

    JNNP: Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts the transition from MCI to dementia

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neuroinflammatory processes such as reactive astrogliosis are common features of neurodegenerative dementias including Alzheimer's disease (AD) and frontotemporal dementia (FT.


    Glial fibrillary acidic protein (GFAP) is an intermediate filament protein mainly expressed in astrocytes of the central nervous syst.


    Glial fibrillary acidic protein (GFAP) is an intermediate filament protein mainly expressed in astrocytes of the central nervous syst.


    GFAP levels doubled in AD patients, but not in bvFTD patien.


    This article was published in the Journal of Neurology, Neurosurgery & Psychiatry Journal of Neurology, Neurosurgery & Psychiatry

    Biomarker-supported diagnosis of AD dementia and MCI due to AD (MCI-A.


    Biomarker-supported diagnosis of AD dementia and MCI due to AD (MCI-A.


    Elevated serum glial fibrillary acidic protein (GFAP) levels in the early stages of Alzheimer's disease (AD)

    A total of 610 patient samples from four clinical centers were investigated for this stu.


    A total of 610 patient samples from four clinical centers were investigated for this stu.


    Serum GFAP asa biomarker for differential diagnosis andprediction ofMCI - to -dementiatransformation_ _ _ frontotemporal dementia and predicts MCI-to-dementia conversion Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:27 April 202Published Online First: doi:11136/jnnp-2021-328547 doi:

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.